Unexpandable lung is a common complication of malignant pleural effusions and inflammatory pleural diseases, such as pleural infection (e.g. empyema and complicated parapneumonic effusion) and noninfectious fibrinous pleuritis. Unexpandable lung due to pleural disease may be because of an active pleural process, and is referred to as malignant or inflammatory lung entrapment. An unexpandable lung may also be encountered in the setting of remote pleural inflammation resulting in a mature fibrous membrane overlying the visceral pleura preventing full expansion of the lung. This condition is termed trapped lung and may be understood as a form of defective healing of the pleural space. Trapped lung typically presents as a chronic, stable pleural effusion without evidence of active pleural disease. An unexpandable lung most often manifests itself as an inability of fully expanding the lung with pleural space drainage. Patients will either develop chest pain preventing complete drainage of the pleural space or develop a postprocedure pneumothorax. Pleural manometry and radiological imaging are useful in the assessment of an unexpandable lung. Pleural manometry can demonstrate abnormal lung expansion during drainage and imaging will demonstrate abnormal visceral pleural thickening found in trapped lung or malignant and inflammatory lung entrapment.
INTRODUCTION
Unexpandable lung resulting in an irreducible pleural space was first described as a complication of therapeutic pneumothorax for the treatment of pulmonary tuberculosis. The complication was reported to occur in up to 5% of patients undergoing therapeutic pneumothorax and thought to be secondary to decreased lung compliance from extensive pulmonary scarring and fibrosis, bronchial obstruction hindering lung inflation and visceral pleural thickening limiting lung expansion. 1, 2 Modern causes of unexpandable lung consist essentially of benign or malignant bronchial obstruction, prolonged atelectasis and visceral pleural thickening, typically resulting from pleural inflammation or malignancy, rather than pneumothorax as mentioned in these historical reports. 3 The common feature of unexpandable lung is the lack of apposition of visceral and parietal pleura at the end of a therapeutic pleural drainage procedure. In normal physiological conditions, resting pleural pressure (at functional residual capacity) is slightly subatmospheric and estimated between −3 and −5 cm H 2 O, a function of the elastic recoil of the lung and the tendency of the chest wall to expand outwards. Introduction of fluid in the pleural space results in decreased lung volumes, a proportionately higher increase in chest wall volume (primarily due to downward displacement of the diaphragm) and development of positive pleural pressure and a hydrostatic gradient. Pleural fluid drainage with normal lung re-expansion results in a decline of pleural pressure down to a more physiological level, which can be illustrated on a pressure-volume curve (Fig. 1A) . Occasionally, a sharp decline in pleural pressure with minimal fluid drainage will be observed, either immediately (in the case of nonexpandable lung, as in Fig. 1B ) or after an initially normal phase (in the case of incompletely reexpandable lung, as in Fig. 1C ). The latter two case scenarios have been termed 'trapped' and 'entrapped' lung, respectively. 4 Pleural fluid formation in the case of a trapped lung is essentially passive, initially due to an ex vacuo (i.e. negative intrapleural pressure) phenomenon. Therapeutic thoracentesis would not be expected to alleviate symptoms in this case. Conversely, lung entrapment implies an active pleural fluid formation process which may result in patient symptoms through increasing pleural pressure, potentially amenable to pleural interventions. An unexpandable lung may be encountered in a variety of clinical scenarios and establishing the presence or absence of an active inflammatory or malignant process is paramount in the management of the condition. The presence of active pleural disease usually requires addressing the underlying process, as well as the potential clinical implications of the unexpandable lung. In the absence of an active process in the presence of unexpandable lung, assessment and management are primarily concerned with the physiological consequences of the unexpandable lung. 3 
CLINICAL PRESENTATION

Chest pain
When pleural fluid drainage continues after the lung has reached maximal lung re-expansion, pleural pressures decrease rapidly, resulting in a sharp increase in transpulmonary pressures. While the pathophysiological mechanism has not been elucidated, excessively negative pleural pressures correlate well with the development of chest discomfort, typically described as anterior, 'pressure-like', often radiating to the neck, and lasting for several minutes after the completion of the thoracentesis. We postulate that the symptoms are due to a pressure effect within the hemithorax, perhaps resulting in mediastinal shift. In one study including 169 thoracenteses, both closing pleural pressure (pressure measured at the end of the procedure) and absolute change in pressure were correlated with chest discomfort. 5 Therapeutic reintroduction of air in the pleural space (therapeutic pneumothorax) usually relieves the pain immediately, and may allow documentation of a thickened visceral pleura if a chest computed tomography (CT) is obtained after the procedure, as intrapleural air contrasts well with the thickened pleura (diagnostic pneumothorax). 6 
Pneumothorax ex vacuo
Occasionally, excessive fluid drainage with negative intrapleural pressure can cause increased transpulmonary pressure. This may result in a pressuredependent parenchymal pleural fistula, with the development of a pneumothorax 'ex vacuo'. In a large study of 265 large-volume thoracenteses, pneumothorax ex vacuo was estimated to occur in 3% of the subjects. 4 These pneumothoraces do not typically require treatment as they result from a re-equilibration of intraand extra-pulmonary pressures. Accordingly, they are typically asymptomatic and may in fact reduce the pain due to negative pleural pressures, similar to therapeutic pneumothorax.
Re-expansion pulmonary oedema
Finally, therapeutic thoracentesis in the case of unexpandable lung has been associated with re-expansion pulmonary oedema (REPE), a condition thought to be secondary to excessively negative pleural pressures and duration of lung collapse, as suggested by two experimental animal studies. 7, 8 While the pathophysiology of REPE remains elusive, stress injury, similar to that observed in ventilator-associated lung injury, could explain the causal role of transpulmonary pressures in this rare complication, estimated to occur in 0.5% of large-volume thoracenteses. 9 An alternative explanation is reperfusion injury leading to pulmonary oedema. 
Pleural fluid analysis
The pleural fluid analysis for a trapped lung is typically a paucicellular transudate or borderline protein discordant exudate. In contrast, the pleural fluid analysis for lung entrapment is always consistent with an exudate. 6 
PLEURAL MANOMETRY
Pleural manometry can provide useful information on the pathophysiology of the pleural effusion and, perhaps, mitigate the risks associated with excessive fluid removal. The measurement of pleural pressure in normal physiological conditions is experimentally challenging due to the narrow normal pleural space. Fortunately, measurement of intrapleural pressure is straightforward as long as sufficient spatial separation of the pleural surfaces is assured. 8 Techniques Different methods have been described to monitor pleural pressure during pleural drainage procedures. The simplest technique is a U-shaped undamped water manometer, using the syringe aspiration system which is part of most standard thoracentesis trays. A disadvantage of this technique is that the large respiratory swings, particularly in dyspnoeic patients, may hinder precise pressure determination. To address this problem, Doelken et al. have reported the use of an overdamped water manometer. 10 The key feature of the overdamped water manometer is the interposition of a 22G needle between the patient and the measuring scale. This needle provides signal dampening and, thereby, minimizes the oscillations of the fluid column. Consequently, mean pleural pressures may be directly read off the measuring scale (Figs 2-3 ). The disadvantage of water manometers is the inability to reliably obtain measurements when the patient develops intermittent cough interfering with valid measurements when air is introduced in the tubing or pleural space. In addition, it is possible that pressure swings due to respiratory movements may have diagnostic value beyond that of mean or end-expiratory pressure values, as suggested by Boshuizen et al. 11 An increase in pressure swings may precede large drops in pleural pressures and represent an early indicator of unexpandable lung. Electronic transducers, described by several investigators, allow monitoring of both static (mean or end-expiratory pleural pressures) and dynamic measures (pressure swings) and may in that regard add diagnostic value. It should be emphasized that there is currently no consensus on the ideal metric in pleural manometry, and further research is needed. Recently, single-use digital handheld manometers have become commercially available. While the data provided compare favourably with that from electronic transducers, the correlation with water manometers, considered the gold standard, is limited at best.
All these techniques allow pleural pressure monitoring, hence provide useful physiological data on pleural elastance facilitating the diagnosis of unexpandable lung. All, however, present the disadvantage of requiring intermittent interruptions of fluid drainage to obtain measurements, typically after each 100-200 mL, resulting in significant 'blind time' periods during which abrupt changes in pleural pressure may be unappreciated. Salamonsen et al. recently reported the use of a continuous manometry system allowing realtime pleural elastance curves which could address this limitation. 12 In practice, measurements obtained towards the end of a drainage procedure are rejected when no more fluid can be withdrawn after the last measurement and/or no residual fluid can be demonstrated by ultrasonography. Towards the end of the drainage, the pleural manometer readings become unreliable as marked changes in pleural pressure occurs with small volume changes, due to local deformation forces developing in the immediate vicinity of the drainage catheter.
Clinical data on the use of manometry
Interpretation of pleural manometry data requires the calculation of pleural space elastance and the plotting of the data points in a pressure/volume diagram. Normal pleural space elastance is <14.5 cm H 2 0/L of pleural fluid removed. The vast majority of pleural pressure/volume curves are monophasic or biphasic, with the terminal segment showing the highest elastance and predictive of an unexpandable lung. Sharp declines in pleural pressures in the absence of pleural fluid occur as a result of local deformation forces around the thoracentesis catheter in patients with an expandable lung. Therefore, it is important to validate the last pleural pressure measurement by either: (i) documenting at least 50 mL of pleural fluid removed or (ii) using ultrasound to document existing fluid around the catheter. Occasionally, in cases of Figure 2 Diagram of a pleural manometry system incorporating an electronic data acquisition system and a U-shaped water manometer. The electronic system consists of a haemodynamic pressure transducer, a signal conditioner, an analogue-to-digital converter and a personal computer-based data acquisition system. The water manometer consists of intravenous tubing attached to a centimetre scale. A 22G needle serves as a resistor and is interposed between the pleural space and the scale. Two three-way stop cocks allow separation of the drainage system from the measurement systems. The electronic pressure transducer and the centimetre scale are zeroed at the level of the insertion site (not shown in the diagram) (Reproduced from Doelken et al., 10 with permission).
tension hydrothorax or lobar atelectasis, an initial steeper descent followed by a normal slope is observed. Presumably, these observations are due to early release of tension or delayed re-expansion of lobar atelectasis during drainage 4,10,13 ( Fig. 1C) .
Impact of pleural manometry on complications of thoracentesis
The current recommendations suggest that pleural fluid drainage be continued until all pleural fluid has been removed, the patient develops pain or pleural pressure becomes more negative than −20 cm H 2 O, a threshold based on limited experimental data. 7, 8 Chest pain associated with negative pleural pressures is common at the end of thoracentesis. The correlation however is not perfect, as suggested by Feller-Kopman et al. 5 In their study, 22% of patients with chest pain and 9% of asymptomatic patients had pleural pressures below −20 cm H 2 O. Using this threshold, Pannu et al. failed to demonstrate that the use of manometry could result in less chest discomfort after the procedure in a large retrospective study.
14 Likewise, in the retrospective study by Heidecker et al., the eight cases of pneumothorax ex vacuo (of 265 large-volume thoracenteses) were not associated with excessively negative pleural pressures. 4 Finally, in a large case series of 185 largevolume thoracenteses during which manometry was used, 5 cases of REPE (1 clinical and 4 radiological) were noted, a rate similar to that reported in other studies. There was no relationship between REPE and the volume removed, but also no relationship with pleural pressure or elastance. 9 Several explanations may account for these disappointing results. First, the studies on pneumothorax and REPE were not powered to identify a potential benefit of manometry in the prevention of these complications. These end points are rare, and adequately powered studies would not be feasible. A randomized controlled trial is currently evaluating the impact of manometry on chest discomfort, and may shed light on the clinical utility of manometry in this setting. Second, as alluded to above, intermittent pressure measurements result in significant blind time during which sharp drops in pleural pressures may be missed, leading to unpredictable complications. Third, the thresholds chosen (− 20 cm H 2 O) or the measures themselves (mean pleural or end-expiratory pressure) may not be adequate, and arguably are based on relatively weak evidence. Finally, it is possible that lung heterogeneity may result in different levels of stress for a given transpulmonary pressure leading less compliant areas to unpredictable regional complications, as described in the acute respiratory distress syndrome. While pleural manometry is a useful tool to support the diagnosis of unexpandable lung, it does not appear, in its present methodology, to prevent complications associated with excessively negative pleural pressures.
CAUSES OF THE UNEXPANDABLE LUNG
The immediate cause of an unexpandable lung due to pleural disease is always mechanical restriction of lung expansion by a visceral pleural peel or pleural thickening. However, the condition causing the pleural peel or thickening may either still be apparent at the time of presentation or may have already resolved. For clinical management purposes, the distinction between an unexpandable lung from an active process and an unexpandable lung from a process that has resolved is important ( Table 1) . The presence of an active inflammatory process, for example empyema or uremic pleuritis, in the setting of the unexpandable lung requires specific treatment directed at the active process; in the examples, antibiotics or treatment of uraemia, as well as consideration of the need to address the mechanical complication by surgical means. 15 The physician has to be mindful that the mechanical complication of an unexpandable lung may resolve with specific treatment of the active process, making it unnecessary to proceed to surgical intervention in some cases.
Although the term trapped lung is often indiscriminately used, as synonymous with an unexpandable lung due to pleural disease, trapped lung should be limited to cases of a chronic pleural effusion in which the inflammatory process has resolved leaving a fibrous visceral pleural peel. This usage of the term trapped lung recognizes the original description of the condition by Moore and Thomas and prevents confusion with clinical entities in which active pleural disease is the predominant clinical feature, which may or may not be accompanied by reversible or irreversible visceral pleural restriction. 16 An unexpandable lung in these cases should be referred to as, for example, malignant lung entrapment or inflammatory lung entrapment.
Histopathologically, the pleural peel or thickening of lung entrapment is distinguished from the pathology of trapped lung by evidence of the active process, such as malignant tissue in malignant lung entrapment or fibrinous pleuritis with an inflammatory, cellular infiltrate in inflammatory lung entrapment. 17 Finally, it should be recognized that the difference between inflammatory lung entrapment and trapped lung is the temporal separation of the initial insult and detection of visceral pleural restriction in trapped lung. In reality, cases may be encountered in which the initial insult has not completely resolved but is clearly not a dominant feature of the presentation. Such cases Figure 3 The 22G needle interposed between the pleural space and the scale of the water manometer dampens the respiratory oscillations and mean pressure can be read directly off the scale (Reproduced from Doelken et al.,
10 with permission).
should be viewed as 'inflammatory lung entrapment in evolution' to trapped lung. (Fig. 5 ) Conceptually, this is not different from scar formation in other tissues in which the sequence of events is an initial insult followed by a fibrinous exudate, a cellular inflammatory infiltrate and progressive fibrous organization and subsequent abatement of inflammation and development of an inert fibrous scar (Figs 4-6) . 6, 17 In summary, the challenges the clinician faces in cases of a pleural effusion in which an unexpandable lung is encountered are the diagnosis of the active pleural process if present, recognition of the need for surgical intervention and the assessment of the pleural equivalent of scar formation at different stages of evolution.
PLEURAL MALIGNANCY
Lung entrapment is a well-known complication of pleural malignancy. Typically, drainage of an entrapped malignant pleural effusion results in chest pain during drainage and the inability to completely evacuate the pleural space, or results in the development of a pneumothorax during drainage. 18, 19 A single study employing pleural manometry has shown a 100% failure rate of pleurodesis when the pleural space elastance exceeded 19 cm/H 2 O/L of fluid removed. 20 However, elastance in this study was only calculated over the first 500 mL of pleural fluid withdrawn. It is therefore uncertain if the findings can be extrapolated to cases in which initial elastance is normal but is followed by an abnormal interval. 20 Surgical decortication is not an option in patients with extensive visceral pleural malignancy, and the best option for palliation appears to be a chronic indwelling catheter and intermittent drainage. Such treatment should only be used if the patient experiences symptomatic relief from drainage, and therefore an initial therapeutic trial of drainage is always warranted to establish the symptom/intervention relationship. 21 Although this has previously been assessed by simply asking the patient what the symptom effect has been, there are now more objective, validated tools specific to pleural disease which may be of use. 22 In summary, an unexpandable lung due to malignant lung entrapment commonly complicates a malignant pleural effusion and the presence of malignant lung entrapment should discourage attempts at chemical pleurodesis. The increasing popularity of outpatient management of malignant pleural effusions with chronic indwelling pleural catheters inadvertently addresses this problem, as the approach is effective regardless of the presence or absence of malignant lung entrapment as long as the patient experiences symptomatic relief from drainage.
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PARAPNEUMONIC EFFUSION AND EMPYEMA
Lung entrapment is a common complication of pleural empyema and complicated parapneumonic effusion and is often accompanied by loculation. In these cases, a fibrinous rind covers the visceral pleura and restricts lung expansion. Generally, this complication is recognized when thoracostomy tube drainage fails to affect full lung expansion. Simple loculation should be distinguished from lung entrapment; the former typically only requires lysis of adhesions to achieve complete drainage, whereas coexisting lung entrapment may require decortication.
The second MIST trial was recently published. This double-blind, double-dummy, factorial randomized trial at 11 centres in the UK documented that intrapleural t-PA (tissue plasminogen activator)-DNase therapy improved pleural drainage in patients with pleural infection, reduced the frequency of surgical referral and the duration of the hospital stay. They also determined that treatment with DNase alone or t-PA alone was ineffective. 26 Assessment of specific effects on lung entrapment was not the purpose of the study, but there are certainly cases where an apparently entrapped lung post pleural infection resolves with treatment of the intrapleural sepsis. Careful clinical judgment is required to assess those patients who require the far more invasive option of thoracic surgery to achieve eventual good lung expansion. 
MISCELLANEOUS CAUSES OF INFLAMMATORY LUNG ENTRAPMENT
It is likely that any inflammatory pleural insult causing fibrinous pleuritis can result in inflammatory lung entrapment. The list includes complicated parapneumonic/empyema, post cardiac surgery pleural effusions, hemothorax, uremic pleural effusions, radiation pleuritis, chemical pleuritis after unsuccessful pleurodesis and rheumatoid pleurisy. Most pleural effusions due to these conditions resolve following treatment or spontaneously. However, if the pleural effusion persists long enough for fibrous organization of the visceral pleural peel to occur, a trapped lung may result. The frequency of this late complication of inflammatory pleuritis is unknown and it is unknown if any therapeutic intervention changes the frequency of development of a trapped lung. It is reasonable to adopt a prudent approach to inflammatory pleural disease, including prompt assessment, diagnosis and initiation of treatment, including an appropriate drainage procedure.
TRAPPED LUNG
In some cases of inflammatory lung entrapment, the fibrinous rind covering the visceral pleura is transformed into a fibrous membrane irreversibly 'trapping' the lung, first described in a small series of patients undergoing surgical decortication for chronic pleural effusions. 16 Trapped lung should be considered in the differential diagnosis of any chronic pleural effusion, especially when the effusion has been stable over time and no active disease that could cause a pleural effusion is clinically apparent. Pleural manometry is helpful in these diagnostically challenging cases as is obtaining a careful history supporting possible pleural inflammation in the past.
Huggins et al. reported a series of 11 patients diagnosed with trapped lung and further clarified the clinical characteristics of trapped lung. 6 Previous coronary artery bypass surgery and uremic pleural effusion were the most common conditions identified as probable causes, with other causes including radiation pleuritis, complicated parapneumonic effusion and spontaneous bacterial pleuritis. 6, 15, [27] [28] [29] Pleural fluid analysis revealed paucicellular lymphocyte-predominant effusions with a low lactate dehydrogenase (LDH), but pleural fluid protein concentrations were in the exudative range in 5 of 11 (45%) cases. 6 The explanation for this discordance may be related to the mechanism of fluid formation in trapped lung. Typical transudative effusions occur under conditions of high solvent filtration due to either increased hydrostatic gradient or decreased oncotic pressure across intact capillary walls. A typical transudative effusion resolves with resolution of the hydrostatic or oncotic disturbance, whereas effusion from trapped lung persists under conditions of low solvent filtration resulting in higher steady-state protein concentrations. Thus, higher protein concentrations found in the effusions due to trapped lung are not due to inflammation-induced capillary leakage but the lack of a dilutional effect of a high solvent filtration condition. In addition, the process resulting in the development of the fibrous visceral pleural membrane may also affect the parietal pleura overlying the diaphragm with consequent impairment of lymphatic bulk flow from the pleural space, thought to be responsible for the removal of most protein from the pleural space under normal conditions. Given these considerations, the finding of a protein discordant exudate should be considered typical for trapped lung. 6 Depending on the size of the effusion, the patient may be symptomatic. In a confidently diagnosed trapped lung in a patient who has significant dyspnoea, surgical decortication should be considered. More often, the effusion is small and asymptomatic and found incidentally. The main 'risk' in these asymptomatic patients is that of multiple diagnostic and attempted therapeutic procedures for a persistent pleural effusion. This is prevented by clinical awareness of this condition, with supportive diagnostic evidence from initial pleural fluid analysis, radiology and, if available, pleural manometry to document an abnormal elastance in chronic effusions. Once the diagnosis of an asymptomatic trapped lung has been established, the patient should be counselled regarding the benign, but irreversible, outcome of this radiographical abnormality. Further diagnostic or therapeutic interventions are not indicated unless the radiographical appearance changes, and patient education should reduce the risk of undergoing an ill-advised intervention in the future.
CONCLUSION
An unexpandable lung due to pleural disease is a common condition complicating malignant and inflammatory pleural disease but may also be encountered as a late consequence of a prior inflammatory pleural disease. Although the unexpandable lung is the final common pathway, the causes of trapped and lung entrapment are distinct in aetiology, treatment and prognosis.
The clinical approach to the patient with an unexpandable lung depends on the nature and activity of the cause of the unexpandable lung. Patients with malignant lung entrapment are best palliated with chronic indwelling pleural catheters and intermittent drainage. It is paramount that relief of dyspnoea following drainage is documented prior to insertion of such catheters. These patients should not undergo attempts at chemical pleurodesis or surgical decortication.
The management of inflammatory lung entrapment is directed at the underlying diagnosis and may or may not include surgical decortication. The decision to proceed to surgery must be individualized and is informed by the evolution of the disease with treatment-the fibrinous pleural peel of inflammatory lung entrapment may resolve with proper drainage and specific therapy.
Trapped lung is best understood as a consequence of defective healing of an inflammatory pleural insult resulting in the formation of a fibrous pleural peel preventing pleural surface apposition. The diagnosis of trapped lung is one of the exclusion and should be strongly considered in a patient with a chronic stable pleural effusion in which the pleural fluid analysis reveals a paucicellular lymphocyte-predominant transudate or protein discordant exudate, particularly when no other condition resulting in pleural effusion exists and the history reveals a remote pleural injury. Once the diagnosis is established, an assessment of the clinical consequences of the condition is required. In selected cases with extensive trapped lung resulting in dyspnoea, surgical decortication is advised, whereas asymptomatic patients should be reassured and further interventions should be avoided.
The most challenging cases are those in which the initial inflammatory pleural condition is resolving but the pleural fluid characteristics are still consistent with pleural inflammation. In these cases, the decision to proceed with further diagnostic interventions or with simple observation must be individualized.
It is of clinical interest if the development of a trapped lung can be prevented. However, this question has not been answered to date but it stands to reason that appropriate drainage and management of inflammatory pleuritis in the acute stage may minimize the frequency of this late complication.
